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Mesenchymal stem cells (MSCs) were originally defined by
their capacity to differentiate into various connective tissue
lineages as well as support hematopoiesis in vitro via the
production of various cytokines, chemokines, and adhesion
molecules [1, 2]. During the past decade, MSCs have been
shown to exhibit angiogenic, trophic, anti-inflammatory, and
immunomodulatory activity using a variety of experimental
paradigms [3–6]. Together with their easy availability and
amenability to large-scale expansion ex vivo, these properties
have propelled MSC-based therapies to the forefront of
regenerative medicine and immune regulatory cell therapy.
Currently, MSCs from a variety of tissue sources are being
evaluated in over 200 clinical trials for the treatment of a
diverse array of disease indications. Completed Phase I and
II clinical trials have reported statistically significant benefits
in patients with steroid-resistant graft versus host disease [7],
severe systemic lupus erythematosus [8], complex perianal
fistulas [9], and ischemic cardiomyopathy [10]. However,
not all trials have met their primary endpoint of efficacy
and while many factors contribute to suboptimal patient
outcomes, key among them are the molecular mechanisms
that govern MSC engraftment, homing, and biodistribution
in vivo. Indeed, despite rapid progress in describing the
therapeutic potency of MSCs in experimental animal models
of disease, progress in understanding their biodistribution
and mechanism of action in vivo has been slow to develop.
For example, robust methodologies to track the fate of
MSCs in vivo are critical toward establishing their tissue
tropism, duration of engraftment, and rates of clearance.
In addition, the identification of endogenous factors that
function as chemoattractants and repellents also plays critical
roles in directing transplanted cells to sites of tissue injury.
Moreover, a clearer understanding of the signaling axes that
regulate MSC trafficking in vivo would provide a means to
direct cells to specific tissue and organs, thereby increasing
overall efficacy of MSC-based therapies. The latter may also
provide a means to mobilize endogenous MSCs and enhance
their regenerative and immune regulatory properties. Finally,
cellular crosstalk and cell-to-cell interactions also likely affect
the biodistribution and survival of exogenously administered
MSCs, but scant information exists regarding these processes
in vivo. In fact, it is a subject of debate whether MSCs
localize to tissue due to passive entrapment in small vessels,
particularly in lung, or if cells employ active mechanisms
similar to leukocytes to home to specific tissues. Therefore,
continued study into themechanism that regulates trafficking
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of endogenous and transplantedMSCswill shed novel insight
into basic MSC biology and lead to the development of more
potent cell-based therapies.
We hope that the readers of this special issue will find it
highly informative. The papers contained within it address
many of the aforementioned issues including methods to
trackMSCs in vivo, mechanisms thatmediateMSCmigration
and homing including within the CNS, and novel delivery
methods to target cells to specific organs. This piece of
information will serve as a useful resource with respect to
current limitations in the field and provide insights as to
how to improve current methods to achieve more beneficial
outcomes for MSC-based therapies.
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